Page 148 - MI-2-4

Microbes & Immunity Glioblastoma therapy: Immunotherapy and inhibitors

multiforme. J Med Life. 2009;2(4):386-393. 42. Jackson CM, Kochel CM, Nirschl CJ, et al. Systemic
tolerance mediated by melanoma brain tumors is reversible
31. Fabian D, Guillermo Prieto Eibl MP, Alnahhas I, et al. by radiotherapy and vaccination. Clin Cancer Res.
Treatment of glioblastoma (GBM) with the addition of
tumor-treating fields (TTF): A review. Cancers (Basel). 2016;22(5):1161-1172.
2019;11(2):174. doi: 10.1158/1078-0432.ccr-15-1516
doi: 10.3390/cancers11020174 43. Lauro GM, Di Lorenzo N, Grossi M, Maleci A, Guidetti B.
Prostaglandin E2 as an immunomodulating factor released in
32. Stupp R, Taillibert S, Kanner AA, et al. Maintenance vitro by human glioma cells. Acta Neuropathol. 1986;69(3-4):
therapy with tumor-treating fields plus temozolomide 278-282.
vs temozolomide alone for glioblastoma: A randomized
clinical trial. JAMA. 2015;314(23):2535. doi: 10.1007/bf00688305
doi: 10.1001/jama.2015.16669 44. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional
role of HLA-G expression in human gliomas: An alternative
33. Canessa A, Del Bono V, Miletich F, Pistoia V. Serum cytokines strategy of immune escape. J Immunol. 2002;168(9):4772-4780.
in toxoplasmosis: Increased levels of interferon-gamma
in immunocompetent patients with lymphadenopathy doi: 10.4049/jimmunol.168.9.4772
but not in AIDS patients with encephalitis. J Infect Dis. 45. Wischhusen J, Friese MA, Mittelbronn M, Meyermann R,
1992;165(6):1168-1170. Weller M. HLA-E protects glioma cells from NKG2D-
doi: 10.1093/infdis/165.6.1168 mediated immune responses in vitro: Implications
for immune escape in vivo. J Neuropathol Exp Neurol.
34. Waksman BH, Adams RD. Allergic neuritis: An experimental 2005;64(6):523-528.
disease of rabbits induced by the injection of peripheral
nervous tissue and adjuvants. J Exp Med. 1955;102(2):213-236. doi: 10.1093/jnen/64.6.523
doi: 10.1084/jem.102.2.213 46. Parney IF, Waldron JS, Parsa AT. Flow cytometry and
in vitro analysis of human glioma-associated macrophages.
35. Louveau A, Smirnov I, Keyes TJ, et al. Structural and Laboratory investigation. J Neurosurg. 2009;110(3):572-582.
functional features of central nervous system lymphatic
vessels. Nature. 2015;523(7560):337-341. doi: 10.3171/2008.7.jns08475
doi: 10.1038/nature14432 47. Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH.
Prospects of immune checkpoint modulators in the treatment
36. Chae M, Peterson TE, Balgeman A, et al. Increasing glioma- of glioblastoma. Nat Rev Neurol. 2015;11(9):504-514.
associated monocytes leads to increased intratumoral and
systemic myeloid-derived suppressor cells in a murine doi: 10.1038/nrneurol.2015.139
model. Neuro Oncol. 2014;17(7):978-991. 48. Hodi FS, O’Day SJ, McDermott DF, et al. Improved
doi: 10.1093/neuonc/nou343 survival with ipilimumab in patients with metastatic
melanoma. [published correction appears in N Engl J Med.
37. Nduom EK, Weller M, Heimberger AB. Immunosuppressive 2010;363(13):1290]. N Engl J Med. 2010;363(8):711-723.
mechanisms in glioblastoma. Neuro Oncol. 2015;17(suppl 7):
vii9-vii14. doi: 10.1056/NEJMoa1003466
doi: 10.1093/neuonc/nov151 49. O’Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy
and safety of ipilimumab monotherapy in patients with
38. Roszman T, Elliott L, Brooks W. Modulation of T-cell pretreated advanced melanoma: A multicenter single-arm
function by gliomas. Immunol Today. 1991;12(10):370-374. phase II study. Ann Oncol. 2010;21(8):1712-1717.
doi: 10.1016/0167-5699(91)90068-5 doi: 10.1093/annonc/mdq013
39. Bodmer S, Strommer K, Frei K, et al. Immunosuppression 50. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and
and transforming growth factor-beta in glioblastoma. immune correlates of anti-PD-1 antibody in cancer. N Engl J
Preferential production of transforming growth factor-beta 2. Med. 2012;366(26):2443-2454.
J Immunol. 1989;143(10):3222-3229.
doi: 10.1056/NEJMoa1200690
40. Huettner C, Czub S, Kerkau S, Roggendorf W, Tonn JC.
Interleukin 10 is expressed in human gliomas in vivo and 51. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for
increases glioma cell proliferation and motility in vitro. metastatic renal cell carcinoma: Results of a randomized
Anticancer Res. 1997;17(5A):3217-3224. phase II trial. J Clin Oncol. 2015;33(13):1430-1437.
41. Huettner C, Paulus W, Roggendorf W. Messenger RNA doi: 10.1200/jco.2014.59.0703
expression of the immunosuppressive cytokine IL-10 in 52. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety
human gliomas. Am J Pathol. 1995;146(2):317-322. of nivolumab, an anti-PD-1 immune checkpoint inhibitor,

Volume 2 Issue 4 (2025) 140 doi: 10.36922/mi.5075